Previous Close | 233.96 |
Open | 232.61 |
Bid | 234.50 x 4000 |
Ask | 238.87 x 800 |
Day's Range | 230.38 - 236.77 |
52 Week Range | 35.61 - 238.42 |
Volume | 2,043,125 |
Avg. Volume | 3,595,850 |
Market Cap | 121.067B |
Beta (5Y Monthly) | 1.36 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.94 |
Earnings Date | Nov 17, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 208.69 |
Speaking of businesses flying high right now, three Fool.com contributors think NVIDIA (NASDAQ: NVDA), Fastly (NYSE: FSLY), and Sea (NYSE: SE) are worth considering if you don't own them yet -- even after triple-digit percentage returns in 2020. Nicholas Rossolillo (NVIDIA): This top semiconductor company is no secret. Driven by its graphics processing technology (historically the realm of high-end video games), NVIDIA has been finding all sorts of new outlets for its chip designs.
Few companies in the drug-development space have offered game-changing potential for their patients quite like Vertex Pharmaceuticals (NASDAQ: VRTX). While all eyes are on COVID-19 vaccine stocks, Vertex is simply dominating the treatment landscape for cystic fibrosis (CF) -- a genetic disease characterized by thick mucus production that can obscure the lungs and pancreas. Although CF doesn't have a cure, Vertex has brought to market a number of gene-based treatments that are improving lung function and quality of life for CF patients.
In the latest trading session, Sea Limited Sponsored ADR (SE) closed at $226.05, marking a -1.57% move from the previous day.